Benelux
3i’s Element bolts on Environ Labs
Deal forms part of Element's acquisitive growth strategy
CVC, Bencis fined in Dutch flour cartel case
Two firms fined around €1m each
Platinum acquires Ten Cate Enbi
GP is carving print roller division out of Royal Ten Cate
Newion invests in 24i Media
Eighth investment for Newion II fund
LLCP opens Dutch office, launches Euro fund
GP's new European fund has target of around €99m
Main Capital backs OnGuard MBO
Firm also provided a mezzanine facility
LuxLeaks: tax exposure not the issue
Leaked tax rulings from Luxembourg cause unexpected irritation for private equity
Season's greetings from the unquote” team
Looking forward to seeing you in the New Year
3i’s Action completes €840m refinancing
Transaction marks second refinancing for Action under 3i's ownership
Equistone backs Unlimited Footwear Group
Business to develop third-party partnerships and pursue international expansion
Standard Investment buys DSM’s Synres division
Euronext-listed Royal DSM is streamlining its Performance Materials division
Adyen raises $250m from General Atlantic et al.
Company will expand further in North America and Asia Pacific
Deal in focus: Karmijn acquires Fred de la Bretonière
A look back at Karmijn's investment in designer shoe brand Fred de la Bretonière
Thuja et al. invest €6m in Cristal
Company will use funds to launch first clinical study of anti-cancer nanomedicine
Advent in partial exit from Mediq
GP took Mediq private for €775m at the beginning of 2013
Parcom invests in Barge Master
GP takes over Frans van Seumeren as majority shareholder
Gores’ Mexx goes bankrupt
Dutch retailer's stores will remain open for now
Egeria to sell NRC
Egeria put NRC on the block earlier this year
Gimv invests €7m in Well Services
Company's CEO and management invested alongside the GP
Gimv sells EBT stake
Gimv has been a shareholder since 1992
Gilde sells Betafence to CVC
CVC bolsters previous 44% stake
Karmijn invests in Estral
Company's founder steps down from board
Vesalius et al. invest €20m in Promethera
Company recently completed phase-I/II trials of its HepaStem product
Gimv et al. exit listed Prosensa
Sale resulted in 4.6x return on historial investment cost for Gimv